Reishi Mushroom Extract in Canada: What 6:1 Means, Licensed Uses, Dose, and Safety

A label-first guide to Ganoderma lucidum fruiting-body extract—without turning a ratio, a mushroom tradition or a different clinical trial into a promise this capsule cannot support.

Reishi has accumulated a larger-than-life reputation. Search results often describe it as an immune booster, sleep aid, stress solution, liver protector and antioxidant—all at once. That makes the shopping decision sound simple: find the biggest extract ratio and assume more benefits.

A better decision starts with the exact bottle. Which part of the mushroom is used? How much extract is in one capsule? What does the extract ratio actually calculate? Which uses are authorized for this Natural Product Number? And how closely does the human research match this preparation and dose?

What is reishi?

Reishi is a common name used for Ganoderma lucidum in the Canadian product licence and Health Canada’s mushroom monograph. The medicinal source can come from cultured mycelium, mycelium or the fruiting body, depending on the licensed product. Biogénique’s current licence specifies the fruiting body—the visible reproductive structure commonly recognized as the mushroom. [1,2,10]

That source detail matters because it tells you what was extracted. It does not, by itself, prove that one product is clinically superior to every mycelium product. Species identity, source part, extraction solvent, ratio, finished-product specifications and any measured marker compounds all contribute different pieces of information. The exact product licence and lot record are more useful than a single front-label adjective.

What does a 6:1 extract mean?

For a concentrated solid extract, Health Canada defines the ratio as crude source material to finished extract. A 6:1 ratio therefore means that six parts of dried source material were used to produce one part of extract. Health Canada calls the corresponding starting-material amount the quantity crude equivalent, or QCE. [3]

The ratio describes material equivalence; it is not a universal potency score. A 6:1 extract is not automatically ‘six times more effective’ than a powder or a different extract. The ratio does not tell you, on its own, the extraction solvent, extraction yield, beta-glucan content, triterpene content, bioavailability or clinical effect. Biogénique’s current product licence lists the ratio and QCE but does not declare a beta-glucan or triterpene standardization. [1,3]

What is this exact product licensed to do?

The safest way to describe a Canadian natural health product is to use the wording attached to its exact NPN. Under NPN 80138908, the current Biogénique Reishi Mushrooms licence authorizes three purpose areas. [1,13]

• Source of antioxidants / provides antioxidants, including wording about helping protect cells against oxidative damage caused by free radicals.

• Used in Herbal Medicine as a liver tonic.

• Used in Herbal Medicine as an adaptogen to help increase energy and resistance to stress when mental and physical fatigue is related to stress.

Those statements are the product-specific boundary. Health Canada’s broader mushroom monograph may list other preparation-dependent claims, including immune-support language for some Ganoderma lucidum preparations. A monograph is licensing guidance; it does not silently add every possible monograph claim to an already issued product licence. [1,2]

What does the human research show?

The human evidence is narrower than the internet’s benefit lists. The most relevant controlled fatigue study enrolled 132 people diagnosed with neurasthenia; 123 were assessable. Participants received a branded Ganoderma lucidum polysaccharide extract at 1,800 mg three times daily for eight weeks. The active group improved more than placebo on clinical severity, fatigue and well-being measures, and the extract was reported as well tolerated. [6]

That study supports continued research on fatigue-related outcomes, but it does not prove the same result from this bottle. The clinical population, branded preparation and 5,400 mg daily extract dose differ from Biogénique’s 1,000 mg daily extract direction. The trial also studied symptoms within a diagnosis that is not equivalent to ordinary work stress or a bad night’s sleep.

A separate randomized double-blind crossover trial gave 26 adults with borderline blood pressure or cholesterol 1.44 g of Lingzhi daily or placebo for 12 weeks. Among 23 evaluable participants, the investigators found no differences in body mass index, blood pressure, plasma antioxidant status or blood lymphocyte subsets. Some metabolic signals appeared, but carry-over effects limited interpretation. [7]

A Cochrane review then evaluated five controlled trials with 398 participants and found that the small body of evidence did not support Ganoderma lucidum for treating cardiovascular risk factors in people with type 2 diabetes. Most included studies had unclear risk of bias, and the pooled findings did not show clinically meaningful improvements in HbA1c, cholesterol, body mass index, fasting glucose, blood pressure or triglycerides. [8]

Together, these findings lead to a restrained conclusion: reishi has studied bioactive constituents and some encouraging signals, but human outcomes depend on the preparation, dose and population. The evidence does not justify promising that a licensed antioxidant/adaptogen capsule will treat a disease or create an immediate feeling.

Antioxidant language: what it does—and does not—mean

The product licence allows antioxidant wording because the finished product was authorized under specific conditions of use. That is not the same as proving that a user will feel an antioxidant effect or that every blood marker will change. In the 12-week crossover trial, plasma antioxidant status did not significantly differ between reishi and placebo. [1,7]

Short-term human biomarker research has also used distinct preparations and endpoints, so it is context for the evidence base rather than proof of an outcome from this capsule. [9]

Antioxidant is also not a synonym for disease prevention. It should not be extended into claims about preventing cancer, heart disease, infection or ageing. The useful consumer message is simpler: the product is licensed as a source of antioxidants, and the product-specific wording should remain within that scope.

Adaptogen language: a gradual support claim, not a stimulant promise

The exact licence uses the phrase ‘adaptogen’ in connection with helping increase energy and resistance to stress when mental and physical fatigue is related to stress. That is not a caffeine-like promise, a treatment for anxiety, or a guarantee of calm. It also does not establish a specific onset time. [1]

A practical way to evaluate this kind of product is to define one modest outcome before starting—such as steadier perceived energy during a demanding month—while keeping sleep, food intake, movement and workload stable enough to interpret the experience. Avoid converting a vague sense of wellness into proof of a mechanism.

How to take Biogénique Reishi

At the licensed direction, a 60-capsule bottle provides 30 days. The two daily capsules supply 1,000 mg of 6:1 extract, equivalent to 6 g of dried fruiting body. The ‘3,000 mg equivalent’ statement is per capsule; it should not be described as 3,000 mg of extract.

Safety and when to ask first

The current product licence requires stopping use if hypersensitivity or allergy occurs. It also directs adults to ask a health care practitioner before use if they have serious or major conditions, any type of acute infection, deficiency or excess, and to ask a practitioner if symptoms persist or worsen. [1]

Those statements should appear clearly and consistently on the current bilingual label and product page. They are more reliable for this exact product than a generic online warning list. A person who is pregnant or breastfeeding, preparing for surgery, taking prescription medication, undergoing cancer treatment, living with liver or kidney disease, or managing an immune condition should still discuss any new mushroom supplement with a qualified health professional before use.

How to compare reishi products without being misled

1. Match the exact NPN. Confirm that the product page, physical label and licence use the same eight-digit number.

2. Check species and part. Ganoderma lucidum and fruiting body should be explicit if that is the intended formula.

3. Separate extract from equivalent. ‘500 mg of 6:1 extract, QCE 3,000 mg’ is different from 3,000 mg of extract.

4. Treat the ratio as characterization, not a clinical score. Extraction solvent, specifications and marker compounds matter too.

5. Read the licensed purpose. A monograph or another brand’s licence does not authorize claims for this product.

6. Read the full direction and count. Two capsules daily turns 60 capsules into a 30-day supply.

7. Ask for a matching lot record. A COA should identify the product and lot and should not be used to promise clinical outcomes.

What a Certificate of Analysis can prove

Biogénique Drive contains a lot-specific file named ‘Biogenique Reishi-082502.pdf.’ Its filename identifies lot 082502, but the scanned PDF did not provide machine-readable text in this verification workflow. No assay, microbial, heavy-metal, identity, date or expiry value is therefore copied into this draft. [12]

Before publication, QA should visually record the product name, lot, manufacturing and expiry dates, specifications, methods, results and approval signatures. The record should also be checked against the current 500 mg 6:1 fruiting-body formula and current inventory. A lot-matched COA can support a statement about that lot meeting listed specifications; it cannot prove stress relief, antioxidant outcomes in a person, superior absorption or clinical effectiveness.

Frequently asked questions

Is reishi the same as Ganoderma lucidum?

Ganoderma lucidum is the proper name used on this Canadian product licence; Reishi is the common name. The source part for this product is the fruiting body. [1,2]

Is 3,000 mg the amount of extract in one capsule?

No. One capsule contains 500 mg of extract. Because it is a 6:1 extract, that amount is equivalent to 3,000 mg of dried fruiting-body starting material. [1,3]

Does 6:1 mean six times more effective?

No. It describes the source-material-to-extract ratio. It does not independently establish marker-compound content, absorption or clinical effect.

Does this Reishi product support the immune system?

The exact NPN 80138908 product licence does not list immune support among its authorized purposes. The current public page should not make that product-specific claim unless the licence is amended and the change is verified. [1]

Can Reishi help with stress-related fatigue?

The product is licensed as an adaptogen to help increase energy and resistance to stress when mental and physical fatigue is related to stress. One randomized trial reported fatigue-related improvements with a different extract at a much higher daily extract dose, so it cannot predict an individual result from this bottle. [1,6]

How long does a 60-capsule bottle last?

Thirty days when used as licensed: one capsule twice daily.

Should I take both capsules together?

The licence says one capsule two times per day and to take with food. It does not direct two capsules at once. Follow the current label on the product received. [1]

Is fruiting body always better than mycelium?

The source part is important, but ‘better’ requires a defined comparison and matching evidence. Fruiting body alone does not prove higher clinical effectiveness, higher beta-glucans or higher triterpenes without product-specific measurements.

Does the COA prove the benefits?

No. A COA can document lot-specific test results against specifications. It does not establish clinical benefits, and the located scanned certificate must be visually verified before any result is published.

Bottom line

Biogénique Reishi under NPN 80138908 is a 500 mg, 6:1 Ganoderma lucidum fruiting-body extract. Each capsule is equivalent to 3,000 mg of dried fruiting body, and the licensed direction is one capsule twice daily with food. The exact licence supports antioxidant, Herbal Medicine liver-tonic and stress-related adaptogen wording. [1]

The honest story is stronger than a long benefits list. A ratio explains how much starting material corresponds to an extract; it does not guarantee six times the effect. Human research includes encouraging and null findings, often using different preparations and doses. The best product decision comes from matching the NPN, formula, dose, claim and lot evidence—not from borrowing the broadest promise on the internet.

Before publication, the live product page must stop mixing the old and new licences, immune/superiority claims must be reconciled, the current label and excipients must be confirmed, and lot 082502’s scanned COA must be read and approved by QA. [4,12]

Related resources

Biogénique Reishi product page

Biogénique Quality Control

Health Canada Licensed Natural Health Products Database

References

1. Health Canada product licence PL-738243 — Biogenique Reishi Mushrooms, NPN 80138908 — issued 3 March 2025; formula, QCE, purposes, dose and risk information

2. Health Canada — Mushrooms natural health product monograph (31 October 2025) — Ganoderma lucidum source parts, preparation-specific claims, doses and risks

3. Health Canada — Quality of Natural Health Products Guide — extract-ratio and quantity-crude-equivalent interpretation

4. Biogénique — Reishi product page — current commerce page; old/new NPN and claim conflicts flagged

5. Google Search Console export — biogenique.com Performance on Search, 17 August 2026 — 16-month query and page opportunity; internal Drive workbook

6. Tang et al. (2005) — randomized, double-blind, placebo-controlled Ganoderma polysaccharide trial — 132 enrolled; 123 assessable; fatigue and well-being outcomes; different extract and dose

7. Chu et al. (2012) — controlled human Lingzhi intervention trial — 26 enrolled; 23 evaluable; 1.44 g/day; no significant plasma antioxidant, blood-pressure or lymphocyte effects

8. Klupp et al. (2015) — Cochrane review of Ganoderma for cardiovascular risk factors — five trials, 398 participants; evidence did not support treatment claims

9. Wachtel-Galor, Tomlinson & Benzie (2004) — controlled human biomarker study — short-term biomarker context; preparation-specific evidence

10. NCBI Bookshelf — Ganoderma lucidum (Lingzhi or Reishi) — source parts, constituents and limits of the human evidence

11. Health Canada issuance letter IL-738243 — NPN 80138908 — licence issuance, quality-attestation and mock-label responsibilities

12. Internal COA — Biogenique Reishi-082502.pdf — lot-identified scanned file; values intentionally withheld pending visual QA verification

13. Health Canada — Licensed Natural Health Products Database — database scope and product-specific NPN fields

Disclaimer

This article is for educational purposes only and is not medical advice. Natural health products are not substitutes for diagnosis or treatment by a qualified health care professional. Follow the current product label. Ask a health care practitioner before use if a medical condition, acute infection, pregnancy, breastfeeding, prescription medication, planned surgery or a complex supplement routine may change the decision. Stop use if hypersensitivity or allergy occurs, and seek care if symptoms persist or worsen.